search
Back to results

Add-on to Micamlo BP Trial

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
Telmisartan + amlodipine
hydrochlorothiazide
Telmisartan + amlodipine
Placebo
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

20 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure (DBP) must be >=90 and <=114 mmHg and mean seated systolic blood pressure (SBP) must be =<200 mmHg
  • Able to stop all current antihypertensive drugs (other than study medication) from Visit 1b through the end of the trial without risk to the patient based on the investigator's opinion
  • Age 20 years or older

Exclusion criteria:

  • Patients with known or suspected secondary hypertension
  • Patients with clinically relevant cardiac arrhythmia
  • Congestive heart failure with New York Heart Association (NYHA) functional class III-IV
  • Patients with recent cardiovascular events
  • Patients with recent stroke events
  • Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers or angiotensin converting enzyme inhibitors; or patients with post-renal transplant or post-nephrectomy
  • Patients with hepatic and/or renal dysfunction
  • Pre-menopausal women who are nursing or pregnant

Sites / Locations

  • 1348.1.015 Boehringer Ingelheim Investigational Site
  • 1348.1.006 Boehringer Ingelheim Investigational Site
  • 1348.1.002 Boehringer Ingelheim Investigational Site
  • 1348.1.005 Boehringer Ingelheim Investigational Site
  • 1348.1.031 Boehringer Ingelheim Investigational Site
  • 1348.1.030 Boehringer Ingelheim Investigational Site
  • 1348.1.033 Boehringer Ingelheim Investigational Site
  • 1348.1.016 Boehringer Ingelheim Investigational Site
  • 1348.1.021 Boehringer Ingelheim Investigational Site
  • 1348.1.024 Boehringer Ingelheim Investigational Site
  • 1348.1.028 Boehringer Ingelheim Investigational Site
  • 1348.1.027 Boehringer Ingelheim Investigational Site
  • 1348.1.001 Boehringer Ingelheim Investigational Site
  • 1348.1.009 Boehringer Ingelheim Investigational Site
  • 1348.1.029 Boehringer Ingelheim Investigational Site
  • 1348.1.014 Boehringer Ingelheim Investigational Site
  • 1348.1.003 Boehringer Ingelheim Investigational Site
  • 1348.1.022 Boehringer Ingelheim Investigational Site
  • 1348.1.004 Boehringer Ingelheim Investigational Site
  • 1348.1.017 Boehringer Ingelheim Investigational Site
  • 1348.1.013 Boehringer Ingelheim Investigational Site
  • 1348.1.018 Boehringer Ingelheim Investigational Site
  • 1348.1.007 Boehringer Ingelheim Investigational Site
  • 1348.1.020 Boehringer Ingelheim Investigational Site
  • 1348.1.025 Boehringer Ingelheim Investigational Site
  • 1348.1.026 Boehringer Ingelheim Investigational Site
  • 1348.1.008 Boehringer Ingelheim Investigational Site
  • 1348.1.032 Boehringer Ingelheim Investigational Site
  • 1348.1.019 Boehringer Ingelheim Investigational Site
  • 1348.1.023 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Telmisartan+amlodipine+HCTZ

Telmisartan+amlodipine

Arm Description

telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet

telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet

Outcomes

Primary Outcome Measures

Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.
Change from baseline in mean seated diastolic blood pressure (DBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.

Secondary Outcome Measures

Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.
Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.
The Proportion of Patients With DBP<90 mmHg and SBP<140 mmHg as Seated Blood Pressure at Trough After 8 Weeks of the Double-blind Period
Patients with trough seated DBP =>90 mmHg or trough seated SBP >=140 mmHg at baseline were analysed.

Full Information

First Posted
October 29, 2013
Last Updated
October 6, 2016
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT01975246
Brief Title
Add-on to Micamlo BP Trial
Official Title
An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Amlodipine 5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Amlodipine 5 mg
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
November 2013 (undefined)
Primary Completion Date
June 2014 (Actual)
Study Completion Date
July 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
This is a multi-centre, randomised, double-blind, active-controlled, parallel-group comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg +hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5 mg) to telmisartan 80 mg+ amlodipine 5 mg (T80/A5 mg) in blood pressure lowering effect at week 8, the end of the double-blind period in essential hypertensive patients who fail to respond adequately to telmisartan 80 mg+ amlodipine 5 mg. Patients are assigned to one of the two groups after a 6-week open-label run-in period taking T80/A5 mg.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
309 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Telmisartan+amlodipine+HCTZ
Arm Type
Experimental
Arm Description
telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet
Arm Title
Telmisartan+amlodipine
Arm Type
Active Comparator
Arm Description
telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet
Intervention Type
Drug
Intervention Name(s)
Telmisartan + amlodipine
Intervention Description
FDC tablet
Intervention Type
Drug
Intervention Name(s)
hydrochlorothiazide
Intervention Description
tablet
Intervention Type
Drug
Intervention Name(s)
Telmisartan + amlodipine
Intervention Description
FDC tablet
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
placebo matching hydrochlorothiazide tablet
Primary Outcome Measure Information:
Title
Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.
Description
Change from baseline in mean seated diastolic blood pressure (DBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.
Time Frame
baseline and week 8
Secondary Outcome Measure Information:
Title
Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.
Description
Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.
Time Frame
baseline and week 8
Title
The Proportion of Patients With DBP<90 mmHg and SBP<140 mmHg as Seated Blood Pressure at Trough After 8 Weeks of the Double-blind Period
Description
Patients with trough seated DBP =>90 mmHg or trough seated SBP >=140 mmHg at baseline were analysed.
Time Frame
baseline and week 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure (DBP) must be >=90 and <=114 mmHg and mean seated systolic blood pressure (SBP) must be =<200 mmHg Able to stop all current antihypertensive drugs (other than study medication) from Visit 1b through the end of the trial without risk to the patient based on the investigator's opinion Age 20 years or older Exclusion criteria: Patients with known or suspected secondary hypertension Patients with clinically relevant cardiac arrhythmia Congestive heart failure with New York Heart Association (NYHA) functional class III-IV Patients with recent cardiovascular events Patients with recent stroke events Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers or angiotensin converting enzyme inhibitors; or patients with post-renal transplant or post-nephrectomy Patients with hepatic and/or renal dysfunction Pre-menopausal women who are nursing or pregnant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1348.1.015 Boehringer Ingelheim Investigational Site
City
Atsubetsu-ku,Sapporo,Hokkaido
Country
Japan
Facility Name
1348.1.006 Boehringer Ingelheim Investigational Site
City
Bunkyo-ku, Tokyo
Country
Japan
Facility Name
1348.1.002 Boehringer Ingelheim Investigational Site
City
Chiyoda-ku, Tokyo
Country
Japan
Facility Name
1348.1.005 Boehringer Ingelheim Investigational Site
City
Chiyoda-ku, Tokyo
Country
Japan
Facility Name
1348.1.031 Boehringer Ingelheim Investigational Site
City
Chiyoda-ku, Tokyo
Country
Japan
Facility Name
1348.1.030 Boehringer Ingelheim Investigational Site
City
Chuo-ku, Tokyo
Country
Japan
Facility Name
1348.1.033 Boehringer Ingelheim Investigational Site
City
Chuo-ku, Tokyo
Country
Japan
Facility Name
1348.1.016 Boehringer Ingelheim Investigational Site
City
Chuo-ku,Sapporo,Hokkaido
Country
Japan
Facility Name
1348.1.021 Boehringer Ingelheim Investigational Site
City
Chuo-ku,Tokyo
Country
Japan
Facility Name
1348.1.024 Boehringer Ingelheim Investigational Site
City
Itabashi-ku, Tokyo
Country
Japan
Facility Name
1348.1.028 Boehringer Ingelheim Investigational Site
City
Itoshima, Fukuoka
Country
Japan
Facility Name
1348.1.027 Boehringer Ingelheim Investigational Site
City
Katsushika-ku, Tokyo
Country
Japan
Facility Name
1348.1.001 Boehringer Ingelheim Investigational Site
City
Kishiwada, Osaka
Country
Japan
Facility Name
1348.1.009 Boehringer Ingelheim Investigational Site
City
Kita-ku, Osaka
Country
Japan
Facility Name
1348.1.029 Boehringer Ingelheim Investigational Site
City
Kita-ku, Osaka
Country
Japan
Facility Name
1348.1.014 Boehringer Ingelheim Investigational Site
City
Kiyose,Tokyo
Country
Japan
Facility Name
1348.1.003 Boehringer Ingelheim Investigational Site
City
Koto-ku, Tokyo
Country
Japan
Facility Name
1348.1.022 Boehringer Ingelheim Investigational Site
City
Mihama-ku, Chiba, Chiba
Country
Japan
Facility Name
1348.1.004 Boehringer Ingelheim Investigational Site
City
Miyagino-ku, Sendai, Miyagi
Country
Japan
Facility Name
1348.1.017 Boehringer Ingelheim Investigational Site
City
Moriya, Ibaraki
Country
Japan
Facility Name
1348.1.013 Boehringer Ingelheim Investigational Site
City
Naka-ku,Yokohama,Kanagawa
Country
Japan
Facility Name
1348.1.018 Boehringer Ingelheim Investigational Site
City
Nishi-ku, Fukuoka, Fukuoka
Country
Japan
Facility Name
1348.1.007 Boehringer Ingelheim Investigational Site
City
Okinawa, Okinawa
Country
Japan
Facility Name
1348.1.020 Boehringer Ingelheim Investigational Site
City
Sakaide, Kagawa
Country
Japan
Facility Name
1348.1.025 Boehringer Ingelheim Investigational Site
City
Sapporo, Hokkaido
Country
Japan
Facility Name
1348.1.026 Boehringer Ingelheim Investigational Site
City
Sapporo, Hokkaido
Country
Japan
Facility Name
1348.1.008 Boehringer Ingelheim Investigational Site
City
Suita, Osaka
Country
Japan
Facility Name
1348.1.032 Boehringer Ingelheim Investigational Site
City
Suita, Osaka
Country
Japan
Facility Name
1348.1.019 Boehringer Ingelheim Investigational Site
City
Takamatsu, Kagawa
Country
Japan
Facility Name
1348.1.023 Boehringer Ingelheim Investigational Site
City
Toshima-ku, Tokyo
Country
Japan

12. IPD Sharing Statement

Links:
URL
http://trials.boehringer-ingelheim.com
Description
Related Info

Learn more about this trial

Add-on to Micamlo BP Trial

We'll reach out to this number within 24 hrs